NCT02366312View on ClinicalTrials.gov

A Phase 2, Single-center, Single-arm, Open Label Trial of Vismodegib in Patients With Keratocystic Odontogenic Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

October 27, 2015

Primary Completion Date

August 31, 2019

Study Completion Date

August 31, 2019

Conditions
Keratocystic Odontogenic Tumor
Interventions
DRUG

vismodegib

vismodegib is a synthetic, small molecule inhibitor of the sonic Hh pathway, which is involved in tumorigenesis, thus providing a strong rationale for its use in the treatment of a variety of cancers.

Trial Locations (1)

10010

NYU Bluestone Center For Cllinical Research, New York

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

NYU College of Dentistry

OTHER